Clinical trial · Interventional
Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas
Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas
NCT00002965CI-TRIAL-00072499completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating patients with recurrent unresectable meningiomas and malignant meningiomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Recombinant Interferon Alfa (INF alpha) | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm 1: Benign Meningiomas
- description
- INF alpha as a subcutaneous injection Monday to Friday for 8 weeks.
- interventionNames
- Biological: Recombinant Interferon Alfa (INF alpha)
- type
- EXPERIMENTAL
- label
- Arm 2: Other Pathologies
- description
- INF alpha as subcutaneous injection Monday to Friday for 8 weeks.
- interventionNames
- Biological: Recombinant Interferon Alfa (INF alpha)
Primary outcomes (1)
- measure
- Number of Patients with Dose Limiting Toxicity (DLT)
- timeFrame
- Each 8 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven tumors: * Unresectable meningioma * Atypical meningioma * Malignant meningioma * Angioblastic meningioma * Hemangiopericytoma * Recurrent or progressive, unresectable tumor after failing radiation therapy or refused radiation therapy following 2 surgeries PATIENT CHARACTERISTICS: Age: * 16 and over Performance status: * Karnofsky at least 60% Life expectancy: * At least 3 months Hematopoietic: * AGC at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * SGPT less than 2.0 times normal * Alkaline phosphatase less than 2.0 times normal * Bilirubin less than 1.5 mg/dL Renal: * BUN less than 1.5 times normal OR * Creatinine less than 1.5 times normal Other: * No active infection * No diseases that obscure toxicity or dangerously alter drug metabolism * No serious intercurrent medical illness * Not pregnant * Fertile patients must use adequate contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * No concurrent biologic therapy Chemotherapy: * Prior chemotherapy allowed and recovered from all myelotoxicity secondary to the therapy Endocrine therapy: * Prior hormonal therapy allowed * No concurrent hormonal therapy Radiotherapy: * Prior radiotherapy allowed Surgery: * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.